Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxiang Anwei Granules is a Traditional Chinese Medicine (TCM) formulation developed by Shenzhen Traditional Chinese Medicine Hospital. It is primarily investigated as an adjunctive therapy for the eradication of *Helicobacter pylori* (H. pylori) infection. The formulation is typically used in combination with standard Western quadruple eradication therapy, which includes a proton pump inhibitor, bismuth, and two antibiotics. In clinical trial settings, Huoxiang Anwei Granules is evaluated for its ability to improve H. pylori eradication rates, alleviate TCM-related symptoms such as gastric distension and pain, improve patient quality of life, and mitigate psychological symptoms like anxiety and depression associated with chronic infection. As a multi-component herbal product, its therapeutic effects are likely mediated through anti-inflammatory, gastroprotective, and potentially indirect antibacterial mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huoxiang anwei granules.